BioSpace News Archive

Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it will release financial results for the first quarter ended March 31, 2022, prior to the open of the U.S. financial markets on Tuesday, May 17, 2022.

Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2022 and provided business highlights.

IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today reported financial results for the quarter ended March 31, 2022.

Cognition Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2022 and provided recent business updates.

Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases, today announced that two posters will be presented at the American Thoracic Society (ATS) 2022 Annual Meeting reporting results from the CORONET and CASCADE studies in patients with COVID-19 pneumonia.

Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the first quarter ended March 31, 2022 and provided an overview of its recent operational highlights.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune ® and Infectimune™ T-cell activating technologies, will discuss its financial results for the quarter ended March 31, 2022, and provide a business update on its conference call today.

PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three months ended March 31, 2022.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the first quarter ended March 31, 2022 and provides a corporate update.

Syndax Pharmaceuticals, Inc. announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a panel discussion on targeted oncology at Citi’s Biopharma Virtual Co-Panel Day on Wednesday, May 18, 2022 at 1:30 p.m. ET.